Mark Foley

Mark Foley

President & CEO

Revance Therapeutics


Mark Foley is an active investor in and board member/chairman for a number of health care companies. Currently, he serves as Chairman of the Board for uLab, HintMD and Arrinex (recently acquired by Stryker) and as a board member for Glaukos Corporation (NYSE: GKOS) were he serves as Chairman of the Compensation, Nominating, and Governance committee and Revance Therapeutics (NASDAQ: RVNC) where he serves as Chairman of the Audit Committee.  Mark is also a Managing Director at RWI Ventures.  Recently, Mr. Foley served as Chairman, President & CEO of ZELTIQ Aesthetics (NASDAQ: ZLTQ) up and through the Company’s acquisition in April of 2017. During Mark’s time at ZELTIQ the company’s market cap grew more than 10x culminating in the sale to Allergan for approximately $2.5B. In 2017, Mark was recognized by Healthegy as the MedTech DealMaker of the year.

Earlier in his career, Mr. Foley held a variety of operating roles in large public companies and venture-backed startups including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. Mr. Foley has over 30 years of medical device operating, investment and CEO experience. Additionally, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new companies. Mr. Foley serves or has served as a Senior Advisor, Executive Chairman, interim CEO and Board Member for a number of medical device companies.

Mr. Foley received his B.A. from the University of Notre Dame in 1987 and is a named inventor on over 13 patents.